CA2632799A1 - Tgf-beta binding compositions - Google Patents

Tgf-beta binding compositions Download PDF

Info

Publication number
CA2632799A1
CA2632799A1 CA002632799A CA2632799A CA2632799A1 CA 2632799 A1 CA2632799 A1 CA 2632799A1 CA 002632799 A CA002632799 A CA 002632799A CA 2632799 A CA2632799 A CA 2632799A CA 2632799 A1 CA2632799 A1 CA 2632799A1
Authority
CA
Canada
Prior art keywords
tgf
seq
antibody
sequence
mature human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002632799A
Other languages
English (en)
French (fr)
Inventor
Bryan Edward Jones
James D. Pancook
Scott William Rowlinson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2632799A1 publication Critical patent/CA2632799A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002632799A 2005-12-23 2006-12-20 Tgf-beta binding compositions Abandoned CA2632799A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75395605P 2005-12-23 2005-12-23
US60/753,956 2005-12-23
PCT/US2006/062397 WO2007076391A1 (en) 2005-12-23 2006-12-20 Tgf-beta binding compositions

Publications (1)

Publication Number Publication Date
CA2632799A1 true CA2632799A1 (en) 2007-07-05

Family

ID=37898733

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002632799A Abandoned CA2632799A1 (en) 2005-12-23 2006-12-20 Tgf-beta binding compositions

Country Status (10)

Country Link
US (3) US7494651B2 (enExample)
EP (1) EP1966243B1 (enExample)
JP (1) JP2009521496A (enExample)
CN (1) CN101346394B (enExample)
AT (1) ATE545657T1 (enExample)
AU (1) AU2006330542B2 (enExample)
BR (1) BRPI0620240A2 (enExample)
CA (1) CA2632799A1 (enExample)
ES (1) ES2379194T3 (enExample)
WO (1) WO2007076391A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101245983B1 (ko) * 2004-03-31 2013-06-28 제넨테크, 인크. 인간화 항-ｔｇｆ-베타 항체
ATE545657T1 (de) * 2005-12-23 2012-03-15 Lilly Co Eli Tgf-beta antikörper
US8350006B2 (en) * 2008-10-24 2013-01-08 Mead Johnson Nutrition Company Methods for determining the bioactivity of TGF-β in a composition
JP5818688B2 (ja) * 2009-01-08 2015-11-18 バイオ−ラッド ラボラトリーズ インコーポレーティッド 核酸増幅反応の効率を改善するための方法および組成物
EP3141561B1 (en) * 2009-04-24 2018-09-12 Vanderbilt University Anti-tgf-beta induction of bone growth
PH12013502489B1 (en) 2011-06-03 2019-04-24 Xoma Technology Ltd Antibodies specific for tgf-beta
WO2013134665A1 (en) 2012-03-08 2013-09-12 Selig Sealing Products, Inc. Container sealing member with protected security component and removal tab
EP2822592B1 (en) 2012-03-08 2018-08-15 Ludwig Institute for Cancer Research Limited Tgf- 1 specific antibodies and methods and uses thereof
CN111000997A (zh) 2013-03-20 2020-04-14 建新公司 用于治疗成骨不全的方法
WO2016024628A1 (ja) * 2014-08-14 2016-02-18 学校法人東京医科大学 樹状細胞の抗癌免疫賦活能の促進方法およびその用途
WO2016115345A1 (en) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Treatment of cancer with anti-lap monoclonal antibodies
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
US10167334B2 (en) 2015-04-03 2019-01-01 Xoma Technology Ltd. Treatment of cancer using anti-TGF-BETA and PD-1 antibodies
EP3307772B1 (en) 2015-06-12 2020-09-09 Ludwig Institute For Cancer Research Limited Tgf-beta 3 specific antibodies and methods and uses thereof
MX2018014047A (es) 2016-05-17 2019-06-20 Genentech Inc Firmas de genes estromales para el diagnóstico y uso en inmunoterapia.
GB201610044D0 (en) 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
US10537637B2 (en) 2017-01-05 2020-01-21 Gensun Biopharma Inc. Checkpoint regulator antagonists
TWI832600B (zh) * 2017-01-20 2024-02-11 美商健臻公司 骨靶向抗體
MX2020004567A (es) 2017-11-06 2020-08-13 Genentech Inc Metodos diagnosticos y terapeuticos para el cancer.
AU2019293047A1 (en) 2018-06-29 2021-01-28 Gensun Biopharma Inc. Antitumor immune checkpoint regulator antagonists
CA3118186A1 (en) 2018-11-05 2020-05-14 Ludwig Institute For Cancer Research Ltd Humanized and variant tgf-.beta.1 specific antibodies and methods and uses thereof
CN113613726B (zh) 2018-11-05 2025-07-15 路德维格癌症研究所有限公司 人源化和变体TGF-β3特异性抗体及其方法和用途
EP3990116A1 (en) 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
CA3152371A1 (en) 2019-08-01 2021-02-04 Vaccinex, Inc. Combined inhibition of semaphorin-4d and tgf.beta. and compositions therefor
AU2021223336A1 (en) 2020-02-19 2022-10-06 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing TGFB antagonist prodrugs useful in the treatment of cancer and methods thereof
CN113563473A (zh) 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
US20240002479A1 (en) * 2020-11-23 2024-01-04 The Regents Of The University Of Michigan Single-chain antibody against flavivirus ns1 protein
WO2022115611A1 (en) 2020-11-25 2022-06-02 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
CN112940119B (zh) * 2021-04-26 2022-05-20 北京芳渟阳生生物科技有限公司 一种单克隆抗体及其与间充质干细胞外泌体的联合应用
CN115707716A (zh) * 2021-08-18 2023-02-21 丹生医药技术(上海)有限公司 一种TGF-β/VEGF双功能抗体融合蛋白
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
WO2023221936A1 (zh) 2022-05-17 2023-11-23 苏州创胜医药集团有限公司 双功能蛋白质及其制剂和用途
EP4599089A1 (en) 2022-10-05 2025-08-13 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
TW202434643A (zh) * 2023-01-09 2024-09-01 大陸商北京拓界生物醫藥科技有限公司 ＴＧＦβ１結合分子、ＧＡＲＰ－ＴＧＦβ１結合分子及其醫藥用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
EP1646655A2 (en) * 2003-07-09 2006-04-19 Eli Lilly And Company Tgf-beta1 ligands
KR101245983B1 (ko) * 2004-03-31 2013-06-28 제넨테크, 인크. 인간화 항-ｔｇｆ-베타 항체
ATE545657T1 (de) * 2005-12-23 2012-03-15 Lilly Co Eli Tgf-beta antikörper

Also Published As

Publication number Publication date
WO2007076391A9 (en) 2008-08-28
US20100136021A1 (en) 2010-06-03
AU2006330542B2 (en) 2012-05-24
US7927593B2 (en) 2011-04-19
AU2006330542A1 (en) 2007-07-05
CN101346394A (zh) 2009-01-14
JP2009521496A (ja) 2009-06-04
US20090155285A1 (en) 2009-06-18
US20080292638A1 (en) 2008-11-27
CN101346394B (zh) 2012-07-25
ES2379194T3 (es) 2012-04-23
EP1966243A1 (en) 2008-09-10
WO2007076391A1 (en) 2007-07-05
BRPI0620240A2 (pt) 2011-11-08
EP1966243B1 (en) 2012-02-15
ATE545657T1 (de) 2012-03-15
US7494651B2 (en) 2009-02-24

Similar Documents

Publication Publication Date Title
US7927593B2 (en) TGF-beta binding antibodies
CA2645358C (en) Humanized monoclonal antibodies to hepatocyte growth factor
US7947811B2 (en) Antibodies that bind specifically to human RON protein
EP3087097B1 (en) Multifunctional antibodies binding to egfr and met
EP3145544B1 (en) Ang2 antibodies
AU2021307516B2 (en) Anti-CLDN-18.2 antibody and use thereof
MX2008008137A (en) Tgf-beta binding compositions
HK1121489B (en) Humanized monoclonal antibodies to hepatocyte growth factor

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20131220